The German pharmaceutical company BioNTech reported a substantial loss in the second quarter as it continues to advance towards the approval of new products, including innovative cancer therapies. The deficit totalled €807.8 million ($886 million) and was therefore significantly higher than the €190.4 million lost in the same period last year, the Mainz-based company said on Monday. In the first half of 2024, the net loss totalled €1.12 billion, compared with €311.8 million in the same period of the previous year. In the second quarter alone, BioNTech said it invested €525.6 million in “non-Co…